AGP Executive Report
Last update: 11 hours agoDrug Safety & Regulation: Dompé’s US arm will pay $32M to settle claims it funded patient assistance foundations to steer purchases of its Oxervate eye drops, a reminder that healthcare marketing tactics can trigger major legal fallout. Migraine Care: AbbVie says atogepant hit all key results in a Phase 3 LUNA study for preventive treatment of menstrual migraine, cutting migraine days around menstruation versus placebo. AI & Biosecurity: Anthropic says it blocked attempts to use Claude AI to model viruses that could be used for biological weapons, adding to pressure on AI firms to prevent misuse. Public Health Access: A breast cancer survivor highlights how women under 40 can face delays in mammograms, pointing to gaps in screening access and referral rules. Healthcare Innovation (Italy-linked): Kaisha Pharma announced an international hub in Italy, signaling continued pharma investment and expansion tied to European operations. Sports Medicine (Italy-linked): F1’s Monza controversy and crash fallout dominated headlines, but the broader theme is athlete safety and medical checks after high-speed incidents.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
